

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listing, of claims in the application.

Claim 1 (original)     A compound having the formula

A-B-C-X-Y

(I)

or a pharmaceutically acceptable salt, ester or prodrug thereof, wherein

A is absent or a nitrogen protecting group;

Y is absent or a carboxylic acid protecting group;

B is absent or is from 1 to about 197 naturally-occurring amino acid residues corresponding to the sequence from about amino acid position 334 to amino acid position 530 of SEQ ID NO:1;

C is R<sup>1</sup>-R<sup>2</sup>-R<sup>3</sup>-R<sup>4</sup> wherein

R<sup>1</sup> is lysyl;

R<sup>2</sup> is leucyl or arginyl;

R<sup>3</sup> is tyrosyl, 3-I-tyrosyl or phenylalanyl;

R<sup>4</sup> is aspartyl; and

X is absent or is from 1 to about 12 naturally-occurring amino acid residues corresponding to the sequence from amino acid position 535 to about amino acid position 546 of SEQ ID NO:1 and homologues and analogues thereof.

Claims 2-68 (cancelled)

Claim 69 (New)     A compound having the formula

A-B-C-X-Y

(I)

or a pharmaceutically acceptable salt, ester or prodrug thereof, wherein

A is absent or a nitrogen protecting group;

Y is absent or a carboxylic acid protecting group;

B is 81 naturally-occurring amino acid residues corresponding to the sequence from amino acid position 450 to amino acid position 530 of SEQ ID NO:1;

C is R<sup>1</sup>-R<sup>2</sup>-R<sup>3</sup>-R<sup>4</sup> wherein

R<sup>1</sup> is lysyl;  
R<sup>2</sup> is leucyl or arginyl;  
R<sup>3</sup> is tyrosyl, 3-I-tyrosyl or phenylalanyl;  
R<sup>4</sup> is aspartyl; and

X is 9 naturally-occurring amino acid residues corresponding to the sequence from amino acid position 535 to amino acid position 543 of SEQ ID NO:1 and homologues and analogues thereof.

Claim 70 (new)      The compound of claim 69 wherein A is absent and Y and B-C-X are as defined therein.

Claim 71 (new)      The compound of claim 69 wherein y is absent and A and B-C-X are as defined therein.

Claim 72 (new)      The compound of claim 69 wherein A and Y are absent and B-C-X is as defined therein.

Claim 73 (new)      The compound of claim 69 wherein A and Y are present and B-C-X is as defined therein.

Claim 74 (new)      The compound of claim 73 wherein A is N-Ac and Y is -NH<sub>2</sub>.

Claim 75 (new)      A method of treating a patient in need of antiangiogenesis therapy comprising administering to a human or animal a therapeutically effective amount of a kringle 5 of a compound of claim 69.

Claim 76 (new)      The method of claim 75 wherein A is absent and Y and B-C-X are as defined therein.

Claim 77 (new)      The method of claim 75 wherein Y is absent and A and B-C-X are as defined therein.

Claim 78 (new)      The method of claim 75 wherein A and Y are absent and B-C-X is as defined therein.

Claim 79 (new)      The method of claim 75 wherein A and Y are present and B-C-X is as defined therein.

Claim 80 (New)      The method of claim 79 wherein A is N-Ac and Y is  $-\text{NH}_2$ .

Claim 81 (new)      A composition comprising the compound of claim 1 and pharmaceutically acceptable excipient.